Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: LivaNova PLC

Market Cap 4.32B 3.81B 3.51B 3.28B 6.15B 407B 6.27B 42.18B 16.34B 201B 16.23B 15.88B 699B P/E 2026 *
28.3x
P/E 2027 * 24.4x
Enterprise Value 4.34B 3.82B 3.53B 3.3B 6.18B 409B 6.29B 42.38B 16.41B 202B 16.3B 15.95B 702B EV / Sales 2026 *
2.88x
EV / Sales 2027 * 2.57x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 68 2015-10-18
Director/Board Member 58 2015-10-18
Chairman 74 2021-06-08
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.64% - - 4.32B
+0.96%+3.15%-33.89%-15.87% 158B
+0.17%+3.22%-6.30%-7.29% 103B
-0.51%-2.64%+54.91%+56.80% 54.84B
+2.55%+3.99%-2.03%+53.47% 54.69B
+2.73%+4.27%-13.94%-42.43% 39.66B
+4.01%+0.77% - - 29.85B
+2.17%-1.04%-19.50%-43.44% 26.59B
+1.70%+5.66%+53.53%-6.35% 23.77B
-0.46%-1.62%-18.36%-4.42% 20.03B
Average +1.33%-2.21%+1.80%-1.19% 56.7B
Weighted average by Cap. +1.16%-1.54%-6.79%-0.61%

Financials

2026 *2027 *
Net sales 1.51B 1.33B 1.22B 1.15B 2.15B 142B 2.19B 14.72B 5.7B 70.13B 5.66B 5.54B 244B 1.61B 1.42B 1.31B 1.23B 2.3B 152B 2.34B 15.75B 6.1B 75.05B 6.06B 5.93B 261B
Net income 146M 129M 119M 111M 208M 13.79B 212M 1.43B 553M 6.8B 549M 537M 23.66B 179M 158M 145M 136M 255M 16.86B 259M 1.75B 676M 8.32B 672M 657M 28.94B
Net Debt 20.06M 17.66M 16.29M 15.23M 28.54M 1.89B 29.08M 196M 75.82M 933M 75.31M 73.68M 3.24B -167M -147M -136M -127M -238M -15.75B -242M -1.63B -632M -7.77B -627M -614M -27.03B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!